Status:
TERMINATED
Ketamine Pilot Study
Lead Sponsor:
Meghan Spyres
Conditions:
Rattlesnake Envenomation
Eligibility:
All Genders
18-100 years
Phase:
PHASE4
Brief Summary
This is a pilot study to evaluate pain responses from two different approved medications (ketamine and fentanyl) in the treatment of pain after rattlesnake envenomation (RSE). Both medications are cur...
Detailed Description
Multiple studies have shown ketamine to be safe and effective agent for acute pain syndromes. RSEs classically result in severe pain that can be difficult to control, despite use of opioids, non-opioi...
Eligibility Criteria
Inclusion
- Ages ≥ 18 years.
- Able to speak and understand English.
- RSE requiring IV pain medication for NRS pain score \> 5.
- No allergy to ketamine or fentanyl.
- Ability to provide informed consent.
- ≤ 24 hours from envenomation.
Exclusion
- Pregnant or lactating.
- Prisoners.
- Refugees.
- History of schizophrenia.
- Clinically intoxicated.
- On buprenorphine therapy.
- History of uncontrolled hypertension
- Increased intracranial pressure
- Systemic envenomation
Key Trial Info
Start Date :
June 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 27 2022
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT05379179
Start Date
June 20 2022
End Date
August 27 2022
Last Update
February 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Banner - University Medical Center, Phoenix campus
Phoenix, Arizona, United States, 85006